Connection
Jennifer Diamond to Retreatment
This is a "connection" page, showing publications Jennifer Diamond has written about Retreatment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.033 |
|
|
|
-
Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar; 15(3):439-47.
Score: 0.033